Eplerenone versus Placebo in the treatment of Acute Central Serous Chorioretinopathy: A Randomized clinical trial.
Leila Rezaei1 *, Pajvak Azadi2 , Ashkan Safarzadeh2
- Associate professor of ophthalmology,Kermanshah university of medical science
- Kermanshah university of medical science
Abstract: Acute Central Serous Chorioretinopathy (CSC), with an incidence of 5.8 in 100,000 persons is an idiopathic disease commonly presented in young men.Different approach exist in this patients .The aim of this study is the comparison of eplerenone with placebo in acute CSC.
Methods: This study conducted on 80 patients in 2 groups with eplerenone and placebo administration in Imam Khomeini hospital. Patients in case group treated with 25 mg eplerenone one daily for a week and then 50 mg daily for three weeks. Control group followed with placebo. Outcomes of treatment measured with visual acuity, macular thickness and choroidal thickness in 500 and 1000 micrometers area of nasal and temporal zone. Data analyzed by SPSS 23.
Results: Mean decrease in macula area and 500 micrometers area of nasal and temporal sides of retina was 105.82±12.90, 95.17±15.48 and 94.45±16.07 respectively. Mean decrease in 1000 micrometers area of nasal and temporal sides of retina was 96.55±17.19 and 96.95±15.89 respectively. Visual acuity LogMar improved from 0.28 to 0.61, statistically significant (P-Value=0.001).
Conclusion: This study confirmed meaningful decrease in macular thickness and choroidal thickness in different area of 500 and 1000 microns in test group. Visual acuity also decreased significantly. This study concluded that acute CSCR treatment with eplerenone reach satisfying responses.
